"Data presented at the conference suggests that GlaxoSmithKline’s investigational drug Lapatinib could one day give Herceptin a run for its money in the breast cancer market.
“We believe that GlaxoSmithKline’s phase II/III efforts with Lapatinib are now set up to potentially ‘take down’ Herceptin in the first-line and adjuvant breast cancer settings over the next few years,” wrote Mr. Holford and colleagues.
Early analysis showed Lapatinib caused a response in 35 to 70 percent of patients. This compares very well against the 20 to 30 percent response rates historically seen for Herceptin in the same setting."
http://www.redherring.com/Article.aspx?a=1...+to+Cancer+Data
Threaded Mode